Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001083986 | SCV000627516 | likely benign | Long QT syndrome | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002316982 | SCV000850862 | likely benign | Cardiovascular phenotype | 2017-03-29 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV000560728 | SCV001148522 | likely benign | not provided | 2022-05-01 | criteria provided, single submitter | clinical testing | CACNA1C: BP4, BP7 |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001706105 | SCV002572192 | benign | not specified | 2022-08-20 | criteria provided, single submitter | clinical testing | |
Clinical Genetics, |
RCV001706105 | SCV001918647 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000560728 | SCV001958144 | likely benign | not provided | no assertion criteria provided | clinical testing |